What is a Patient Information Leaflet and why is it useful?
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL 20046/0270 .
Ofcram PR 200mg Prolonged Release Capsules, Hard
Package Leaflet: Information for the patient
Ofcram PR 200mg Prolonged Release Capsules, Hard
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet:
1. What Ofcram Prolonged Release Capsules are and what they are used for
2. What you need to know before you take Ofcram Prolonged Release Capsules
3. How to take Ofcram Prolonged Release Capsules
4. Possible side effects
5. How to store Ofcram Prolonged Release Capsules
6. Contents of the pack and other information
1. WHAT OFCRAM PROLONGED RELEASE CAPSULES ARE AND WHAT THEY ARE USED FOR
You must talk to a doctor if you do not feel better or if you feel worse after a few days.
Ofcram PR 200mg Prolonged Release Capsules (called Ofcram Prolonged Release Capsules throughout the rest of this leaflet) contain a medicine called dipyridamole. Ofcram belongs to a group of medicines called antithrombotic agents which are used to stop blood clots forming.
Ofcram Prolonged Release Capsules are used:
- After a stroke to prevent blood clots in the brain
- To prevent blood clots forming after having a heart valve replaced.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE OFCRAM PROLONGED RELEASE CAPSULES
Do not take Ofcram Prolonged Release Capsules:
- If you are allergic to dipyridamole, or any of the other ingredients in this medicine (listed in Section 6).
Warnings and precautions
Talk to your doctor or pharmacist or nurse before taking Ofcram Prolonged Release Capsules if you have:
- Angina or other heart problems (including heart valve or circulation problems) or have recently had a heart attack
- Myasthenia gravis (a rare muscle problem)
- Bleeding problems
- Or if you are pregnant, planning to become pregnant or breast-feeding.
Other medicines and Ofcram Prolonged Release Capsules
Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines. This includes medicines obtained without a prescription, herbal medicine, strong vitamins and minerals. This is because Ofcram Prolonged Release Capsules can affect the way some other medicines work. Also some other medicines can affect the way Ofcram Prolonged Release Capsules work.
Tell your doctor or pharmacist if you are taking medicines for:
- High blood pressure
- Heart problems or irregular heartbeat (e.g. adenosine)
- Blood clots (e.g. warfarin, aspirin)
- Myasthenia gravis, a disease which causes muscle weakness (e.g. cholinesterase inhibitors).
If you are having heart tests
Always tell your doctor that you are taking Ofcram Prolonged Release Capsules before having a test of your heart function (myocardial imaging). Treatment with Ofcram Prolonged Release Capsules may affect the results. You may need to stop taking Ofcram Prolonged Release Capsules before you have the test. Dipyridamole is also sometimes given as an injection during tests to see if the heart is working properly (also called ‘myocardial imaging’). This means that the test and your medicine may contain the same substance. If you are going to have an injection of dipyridamole, tell the doctor that you are taking Ofcram Prolonged Release Capsules.
Ofcram Prolonged Release Capsules with alcohol
You should avoid alcohol when taking the capsules.
Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
If you are pregnant you are not recommended to take Ofcram Prolonged Release Capsules. Ask your doctor for advice.
If you are breast-feeding, do not take Ofcram Prolonged Release Capsules, as Ofcram is excreted into breast milk. Talk to your doctor.
No data are available.
Driving and using machines
You may experience dizziness whilst taking Ofcram Prolonged Release Capsules. If this occurs you should not drive or operate machinery.
Ofcram Prolonged Release Capsules contains sucrose and sodium benzoate.
- If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product
- This medicine contains 0.02 mg sodium benzoate in each dosage unit
- This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially ‘sodium-free’.
3. HOW TO TAKE OFCRAM PROLONGED RELEASE CAPSULES
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is:
Use in adults
The recommended dose is one capsule twice daily, usually one in the morning and one in the evening.
The capsules should be swallowed whole without chewing.
Use in children
Ofcram Prolonged Release Capsules are not recommended in children.
If you take more Ofcram Prolonged Release Capsules than you should
Tell your doctor, hospital or pharmacist straight away if you have taken more Ofcram Prolonged Release Capsules than listed here or more than the doctor has prescribed and you feel unwell. Take the medicine pack with you, even if there are no capsules left.
If you forget to take Ofcram Prolonged Release Capsules
If you forget a dose, take it as soon as you remember it. However, if it is time for the next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose.
If you stop taking Ofcram Prolonged Release Capsules
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
4. POSSIBLE SIDE EFFECTS
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience any of the following side effects after you have taken your medicine, see your doctor immediately. These side effects are rare but serious:
- Severe allergic reaction which may include a red and lumpy skin rash, difficulty breathing, swelling of face, mouth, lips or eyelids, unexplained high temperature (fever) and feeling faint. If the swelling affects your throat and makes breathing and swallowing difficult, stop taking your medicine and go to hospital straight away.
Very common (may affect more than 1 in 10 people)
- Feeling dizzy
- Feeling sick (nausea).
Common (may affect up to 1 in 10 people)
- Worsening of the symptoms of heart disease such as chest pain and shortness of breath
- Being sick (vomiting)
- Muscle pain.
Not known (frequency cannot be estimated from available data)
- Increased heart rate
- Lowering of blood pressure
- Hot flushes
- Tightening of the chest
- Pale, raised, itchy areas of skin with red edges
- A blood problem called “thrombocytopenia” which can cause bruising and prolong bleeding from wounds or during and after surgery
- Gallstone pain (in the centre or right of your stomach). In people who have gallstones, the dipyridamole in this medicine can be absorbed into the gallstones.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5. HOW TO STORE OFCRAM PROLONGED RELEASE CAPSULES
Keep this medicine out of the sight and reach of children.
Do not store above 25°C.
Keep the container tightly closed in order to protect from moisture.
Do not open the container until you are ready to start taking the capsules. If you have any capsules left after six weeks, these should not be taken.
Do not use this medicine after the expiry date which is stated on the label and carton afte Exp:. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. CONTENTS OF THE PACK AND OTHER INFORMATION
What Ofcram Prolonged Release Capsules contain
The active substance is dipyridamole. Each capsule contains dipyridamole 200mg.
The other ingredients are: tartaric acid pellets [tartaric acid, sucrose and povidone], hypromellose, talc, acacia, spray-dried, triacetin, povidone, simeticone emulsion (30 % W/V) [simethicone, cetostearyl alcohol and ethoxylate, sodium benzoate], methacrylic acid - ethyl acrylate copolymer, hypromellose phthalate P55.
Capsule shells: gelatin, titanium dioxide (E171), red and yellow iron oxides (E172).
What Ofcram Prolonged Release Capsules look like and contents of the pack
Hard gelatin capsules consisting of a red cap and an orange body. Dimension 7,66 mm x 23,1 mm.
The capsule contains yellow coloured slow release pellets.
HDPE bottle with polypropylene child resistant closure, containing a desiccant in a pillow pouch.
Packs contain 60 capsules.
Marketing Authorisation Holder and Manufacturer
The Marketing Authorisation Holder is:
85 King William Street
The Manufacturer is:
18 Owen Drive
This leaflet was last revised in May 2018.